Research programme: bacterial glycosyltransferase inhibitors - GLYCODesign
Latest Information Update: 22 Aug 2002
At a glance
- Originator GLYCODesign
- Mechanism of Action Glycosyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 22 Aug 2002 Discontinued - Preclinical for Bacterial infections in Canada (unspecified route)
- 07 Dec 1998 Preclinical development for Bacterial infections in Canada (Unknown route)